adjuvant system relying on the use of anti-CD40 antibodies mode of action may allow the system to be used in combination with other adjuvants and in situations where existing systems don't work Proof of concept achieved in pre-clinical studies Interested in partnering for vaccine development and to source anti CD40
Missing: Adjuvantix's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Adjuvantix's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Adjuvantix Frequently Asked Questions (FAQ)
When was Adjuvantix founded?
Adjuvantix was founded in 1999.
What is Adjuvantix's latest funding round?
Adjuvantix's latest funding round is Other Investors.
Who are the investors of Adjuvantix?
Investors of Adjuvantix include Aberdeen Asset Management, White Rose Technology Seedcorn Fund and Fusion IP.
Who are Adjuvantix's competitors?
Competitors of Adjuvantix include ISA Pharmaceuticals, Immune Design, Sutro Biopharma, Profectus BioSciences, Vaxart and 11 more.
Compare Adjuvantix to Competitors
ModiQuest (CRO) focus is on generation of recombinant monoclonal antibodies (animal, human). The company use antigen specific B-cell selection combined with efficient hybridoma generation or direct antibody cDNA cloning from selected B-cells. MQR offers custom phage display services.
nnFor more than fifty years, the company have been plotting the route in Allergy medicine. The company have been leading generations of allergists to some of the most discoveries in this science:na vaccine by bronchial route, a vaccine by nasal route, the Methacholine Challenge Test, the Test Dose for foodstuff or additives allergy, and allergens adsorbed on single-use needles.
IBI has recently demonstrated that treatment of Bacillus anthracis infected mice with a combination of the antibiotic ciprofloxacin and partially purified antibodies against anthrax protective antigen increased survival rates in comparison with antibiotic treatment alone.
CoImmune, fka Argos Therapeutics, is a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases. Using biological components from each patient, the company's immunotherapies employ the patient's dendritic cells to activate an immune response specific to the patient's disease.
Vaxent has developed a StepNovA vaccine for Group A streptococcus
ImmBio is a vaccine company developing vaccine systems. The portfolio addresses areas of high unmet need, where the risk and consequence of infection are severe.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.